Molecular Templates, Inc.

Abeome Corporation

Crystal Jackson

Richard Shimkets

Thomas Vincent

Erin Willert

Eric Poma

Hilario Ramos

Nathan Bartlett

Yonghua Luo

Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MHC class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).

PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds

Disclosed are compositions and methods related to IL-25 binding molecules.

Neutralizing monoclonal antibodies to IL-25 and uses thereof

PD-L1 -binding molecules comprising Shiga toxin A subunit scaffolds

Growing community of inventors

Jefferson, GA, United States of America

Crystal Jackson